Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP1153 | DOI: 10.1530/endoabs.41.EP1153

ECE2016 Eposter Presentations Thyroid cancer (81 abstracts)

Thyroid cancer in a patient with neurofibromatosis type 1: von recklinghausen disease

Ioannis Karaitianos 1 , Panagiotis Athanassiou 2 , Christiana Tsomidou 3 & Ifigenia Kostoglou-Athanassiou 4

15 views


1Department of Surgery, St. Savvas Hospital, Athens, Greece; 2Department of Rheumatology, St. Paul’s Hospital, Thessaloniki, Greece; 3Department of Medicine, Hippocrates Hospital, Piraeus, Greece; 4Department of Endocrinology, Red Cross Hospital, Athens, Greece.


Introduction: Neurofibromatosis type 1 or von Recklinghausen disease is a systemic hereditary disease characterized by disorders regarding the skin, neural and skeletal systems. Osteoporosis is one of the skeletal manifestations of neurofibromatosis type 1, being associated with increased fracture risk. Neurofibromatosis type 1 is associated with a propensity for the development of cancer, breast cancer in particular being associated with neurofibromatosis type 1.

Aim: The aim was to present the case of a patient with neurofibromatosis type 1 who developed breast and thyroid cancer and was diagnosed with osteoporosis.

Case report: A female patient, aged 47, with neurofibromatosis type 1 developed breast cancer at the age of 45 and had surgery and radiotherapy. The patient had a mother with neurofibromatosis type 1, who had breast cancer and had died from metastatic generalized breast cancer. A year later the patient presented with a nodule in the thyroid gland. Fine needle aspiration biopsy was performed and revealed the presence of papillary thyroid cancer. Near total thyroidectomy was performed and histology was positive for a papillary thyroid cancer. The patient complained for diffuse musculoskeletal pain, 25(OH)D3 levels and bone mineral density were measured. 25(OH)D3 levels were 20 ng/ml, T score was −2.9. Ibandronate was administered at a dose of 150 mg once monthly along with calcium and vitamin D orally. A year later bone mineral density was measured, T score being −2.7, compatible with improvement in bone mineral density.

Conclusions: Neurofibromatosis type 1 is a systemic hereditary disease characterized by a tendency for the development of cancer. Recently, osteoporosis has been described as one of the features of the disease. The case of a patient has been described with neurofibromatosis type 1 and osteoporosis who improved after treatment with risedronate (Benlidayi et al. 2015). The patient described herein was also given bisphosphonates with a good therapeutic response.

Article tools

My recent searches

No recent searches.